Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
With the narrow SAR of the tail favouring the
2019-07-29
With the narrow SAR of the tail favouring the ortho sulfone group, we examined the remaining position open to substitution at the pyrazole 3-position, in an attempt to at least moderate the excessive human PPB (). Lipophilic groups in this position maintained huge shifts in potency in the absence or
-
As suggested by previous data
2019-07-29
As suggested by previous data [45], we identified that the N-terminal and C-terminal domains of DDX3 were enriched in intrinsically disordered regions (Fig. 6). We also found that this characteristic was conserved in the external domains of several homologs of DDX3 (from yeast to human) and all desc
-
The causes of POD are complex and not entirely clear
2019-07-29
The causes of POD are complex, and not entirely clear. Androsova et al, believed that the main molecular mechanism of POD is a central cholinergic deficiency caused by deregulation of cholinergic anti-inflammatory pathways leading to increased inflammation. The cholinergic anti-inflammatory pathway,
-
Because EBI is expressed on the major subsets of immune
2019-07-29
Because EBI2 is expressed on the major subsets of immune cells, and small molecule antagonists for EBI2 were recently described (Benned-Jensen et al., 2013, Gessier et al., 2014), EBI2 constitutes a tempting drug target reminiscent of the sphingosine-1-phosphate receptor superagonist fingolimod/Gile
-
T-5224 Our western blotting results showed that
2019-07-27
Our western blotting results showed that phospho-DDR1 levels continued to increase after I/R injury, and the overall activation trend between phospho-DDR1 and MMP-9 was the same. We found that phospho-DDR1 expression started to increase significantly at 12h after I/R injury, which may be related to
-
ABT 702 dihydrochloride Yet the standards fall back on the d
2019-07-27
Yet, the standards fall back on the development process with justification. As shown by Littlewood and Strigini (1993), the extent to which the reliability of software (both OTS and bespoke) can be proved by testing is severely limited––not because appropriate tests cannot be devised, but because ad
-
br Acknowledgments Denise Fernandes acknowledges a
2019-07-27
Acknowledgments Denise Fernandes acknowledges a postdoc fellowship (SFRH/BPD/34289/2006) from the Portuguese Fundação para a Ciência e Tecnologia (FCT) of the Ministry of Science and Technology of Portugal. This work was supported by the Spanish National Plan for Research (Project Ref. CGL2011-24
-
br Discussion Variable estradiol effects
2019-07-27
Discussion Variable estradiol effects on cell proliferation have been reported according to animal species, tissues, and type of estrogen receptor [16,21,22,[29], [30], [31]]. In the kidney, 17βE was found to increase [3H]-thymidine incorporation in primary rabbit kidney proximal tubule N,N-Dimet
-
ACE also known as Kininase II is an important enzyme
2019-07-27
ACE also known as Kininase II is an important enzyme of the Renin angiotensin ASP015K system (RAAS) (Novo et al., 1987), it is believed to be a potent blood pressure regulator and also plays a crucial role in activation of the bradykinin receptor via inactivation of bradykinin which works to induce
-
Dual inhibition of ACE and NEP as a
2019-07-27
Dual inhibition of ACE and NEP as a strategy for treating hypertension has been extensively investigated, including contributions from these laboratories through the discovery of Sampatrilat . Given that both targets are related zinc metalloproteinases, dual enzyme inhibition can be achieved within
-
An even more striking difference
2019-07-27
An even more striking difference is observed when comparing active site residues, which are evolutionarily very well conserved in other soluble PPases 18, 19. In 31 known PPase sequences, 13 functionally important active site residues are conserved in all sequences, but only two of them (D70 and D97
-
The cyclin dependent kinase deactivation is carried out by
2019-07-27
The cyclin-dependent kinase deactivation is carried out by a particular group of proteins cyclin-dependent kinase inhibitors (CDKIs). These group of proteins blocks kinase activity by interfering with the interaction of cyclin-CDK complex [43]. The inhibition of CDK naturally occurs during a G1 phas
-
Some pyrimidine analogs are substrate based inhibitors that
2019-07-26
Some pyrimidine analogs are substrate-based inhibitors that bind to the dihydroorotate binding site, but most reported inhibitors of DHODH bind to the site occupied by the ubiquinone co-factor., , , , , , , , , , , , , , , , , X-ray crystallographic studies of inhibitor complexes with DHODH and DHO
-
p is a tumor suppressor gene that inhibits cyclin
2019-07-26
p16 is a tumor-suppressor gene that inhibits cyclin-dependent kinase 4 and 6 activities and arrests the LY 2389575 hydrochloride where in the G1 phase. Aberrant methylation and mutation of p16/MTS1 in OSCC of patients was found in our previous study. Moreover, the frequency of hypermethylation of p1
-
br an anaerobic gram positive spore
2019-07-26
, an ITD 1 gram-positive, spore-forming bacterium that can induce fatal intestinal inflammatory disease, is the most prevalent cause of antibiotic-associated diarrhea and pseudomembranous colitis in nosocomial settings. Two exotoxins, toxin A (TcdA) and toxin B (TcdB), secreted by the bacterium,
15332 records 971/1023 page Previous Next First page 上5页 971972973974975 下5页 Last page